Strides Shasun has achieved closure for divestment of India brand business to Eris Lifesciences. In November, Strides Shasun had entered into definitive agreements with Eris Lifesciences for sale of its branded generics business to Eris for an aggregate cash consideration of Rs 500 crore.
Strides Shasun (formerly known as Strides Arcolab) is engaged in manufacturing, sale and export of pharmaceutical products. It offers general tablets, hard gelatin and soft gelatin capsules, sachets, potent drugs and semi-solids.
